Vertex Entered into a Non-Exclusive License Agreement with CRISPR Therapeutics to Advance Hypoimmune Cell Therapies for Type 1 Diabetes
- CRISPR Therapeutics to receive $100M up front for non-exclusive rights to CRISPR Therapeutics’ technology for hyperimmune gene-edited cell therapies & ~$230M in research & development milestones along with royalties on any future products
- Vertex to get non-exclusive rights to accelerate the development of potentially curative cell therapies for T1D using CRISPR Therapeutics’ gene editing technology CRISPR/Cas9
- CRISPR Therapeutics continues to expand its capabilities in regenerative medicine and advance existing allogeneic gene-edited cell therapy programs. The P-I/II study of VCTX211, an allogeneic, gene-edited, stem cell-derived product candidate has been initiated and is ongoing for T1D
Ref: vertex | Image: vertex
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.